Targeting the Multi-Factorial Root Causes of CVD
We are a Michigan bio-sciences group that shares a scientifically supported hypothesis that cholesterol is not the cause of Atherosclerosis and that there is no such thing as ‘bad’ cholesterol as it is essential for overall health and well-being.
We're proud to introduce first-in-class diagnostic panels (GlycoCardia) and triple compound oral therapy (Embotricin) innovations that may prove to be a profound breakthrough in the pursuit to predict, prevent and cure Cardiovascular Disease (CVD).
36 Month Target
In-human, proof of principle against hypertension, heart failure and coronary heart disease.
Emmy award winning television and film personality Kim Adams interviews Mike Brennan, Arterez CEO, at NRM Streamcast™ in Detroit.
Offerings and IP Summary
"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."
Dr. Joe Tunac
Primary Offerings
IP Matter Description
Embotricin™
A rationally synthesized, triple compound, oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.
GlycoCardia™
Diagnostic panels that provide specific information on the associated pathology and risk factors of multiple CVD diseases and stages of same based on our Glycocardia Detritus Fingerprint™ technology.
Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Glycocalyx Disruption.
Biomarkers of Vascular Disease.
Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
Oxidative Damage.
(Draft) Animal Model for CVD and Inflammation.
